Baird Starts NewLink Genetics (NLNK) at Outperform; Major Player In A Field That's Starting To Come Into Its Own

Baird initiates coverage on NewLink Genetics (NASDAQ: NLNK) with a Outperform. PT $10.00.

Baird analyst says, "While key value-enhancing Phase III data events are at least a year off, we think positive existing Phase II data, combined with what we view as a reasonable valuation provide for a compelling enough reason to buy this name now. Given the high risk/high reward nature of this story, we would not necessarily advise a focused exposure here, but do think it makes a good addition to any aggressive growth-oriented portfolio."

For an analyst ratings summary and ratings history on NewLink Genetics click here. For more ratings news on NewLink Genetics click here.

Shares of NewLink Genetics closed at $7.00 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
• UBS Starts Schrodinger (SDGR) at Neutral
• JPMorgan Resumes SanDisk (SNDK) at Overweight